Emprumapimod hydrochloride

• CAT Number: I041421
• Molecular Formula: C24H30ClF2N5O3
• Molecular Weight: 509.98
• Purity: ≥95%
• Synonyms: N-[(2S)-1-amino-4-(dimethylamino)-1-oxobutan-2-yl]-5-(2,4-difluorophenoxy)-1-(2-methylpropyl)indazole-6-carboxamide;hydrochloride
• IUPAC Name: N-[(2S)-1-amino-4-(dimethylamino)-1-oxobutan-2-yl]-1-tert-butyl-5-(2,4-difluorophenoxy)indazole-6-carboxamide;hydrochloride
• InChI: InChI=1S/C24H29F2N5O3.ClH/c1-24(2,3)31-19-12-16(23(33)29-18(22(27)32)8-9-30(4)5)21(10-14(19)13-28-31)34-20-7-6-15(25)11-17(20)26;/h6-7,10-13,18H,8-9H2,1-5H3,(H2,27,32)(H,29,33);1H/t18-;/m0./s1
• InChIKey: GMECXURSFLRLFD-FERBBOLQSA-N
• SMILES: CC(C)(C)N1C2=CC(=C(C=C2C=N1)OC3=C(C=C(C=C3)F)F)C(=O)N[C@@H](CCN(C)C)C(=O)N.Cl

Emprumapimod hydrochloride（Cat No.:I041421）is a selective inhibitor of p38 mitogen-activated protein kinase (MAPK), a key enzyme involved in the regulation of inflammatory and stress response pathways. By inhibiting p38 MAPK, Emprumapimod hydrochloride can reduce the production of pro-inflammatory cytokines, making it a potential therapeutic agent for conditions characterized by excessive inflammation, such as autoimmune diseases, rheumatoid arthritis, and chronic obstructive pulmonary disease (COPD). Additionally, its ability to modulate cellular stress responses and immune activation provides promise for broader applications in inflammation-related disorders and other diseases with dysregulated immune function.